TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11931374
Drug: Fibrinogen adsorption
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen adsorption treatment
Study: 8749600
Drug: Progestogen-only pill
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen-only pill (POP)
Study: 2390880
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg daily
Study: 2390880
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg daily
Study: 350232
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg daily
Study: 2390880
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg daily
Study: 2390880
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (control)
Study: 6117302
Drug: Intravenous rimiterol
Normalized name: rimiterol
DrugBank: Rimiterol (DB13559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rimiterol (1050 microgram cumulative dose over 90 min)
Study: 6117302
Drug: Intravenous rimiterol
Normalized name: rimiterol
DrugBank: Rimiterol (DB13559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rimiterol
Study: 31557763
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticagrelor for 1 month followed by 23-month ticagrelor monotherapy
Study: 31557763
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus either clopidogrel or ticagrelor for 12 months followed by 12-month aspirin monotherapy
Study: 28139362
Drug: Completion axillary
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion axillary lymph node dissection (cALND) - standard treatment
Study: 19953915
Drug: Dexamethasone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 10 mg IV (Group D)
Study: 19953915
Drug: Methylprednisolone, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, 120 mg IV (Group M)
Study: 19953915
Drug: Normal saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, 10 ml IV (Group S)
Study: 17329696
Drug: rHEV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHEV vaccine
Study: 16272454
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy and adjuvant chemotherapy
Study: 16272454
Drug: Novel molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel molecular targeted therapies (trastuzumab)
Study: 11835924
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg 3 times daily or diclofenac 75 mg twice daily
Study: 10800498
Drug: Cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine therapy (interferon-alpha)
Study: 10800498
Drug: Cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine therapy (interleukin-2)
Study: 10800498
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies (cytotoxic chemotherapies)
Study: 10800498
Drug: Immunotherapy approaches
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy approaches
Study: 1688980
Drug: Nifedipine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (0.3 micrograms/kg/min infusion)
Study: 1688980
Drug: Enoximone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.5 mg/kg bolus)
Study: 6784924
Drug: Mannitol (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (37.5 g by 6-hour infusion)
Study: 6784924
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2 every 21-28 days)
Study: 26547100
Drug: REG1 (pegnivacogin
Approvals — FDA: no, EMA: no, PMDA: no
Description: REG1 (pegnivacogin 1 mg/kg bolus followed by 80% reversal with anivamersen)
Study: 22133650
Drug: Verapamil-sustained-release-led (Ve-led)
Normalized name: verapamil Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil-sustained-release-led (Ve-led) treatment strategy
Study: 22133650
Drug: Atenolol-led (At-led)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-led (At-led) treatment strategy
Study: 18337008
Drug: AMG 517
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 517 (TRPV1 antagonist)
Study: 16508298
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for 4 weeks, 10 mg/day thereafter)
Study: 14624937
Drug: 2.0 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/kg/d protein feeding regime
Study: 14624937
Drug: Escalating isocaloric
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating isocaloric protein feeding regime (1.5, 2.0, and 2.5 g/kg/d)
Study: 14624937
Drug: 2.5 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/kg/d protein intake
Study: 14624937
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (if enteral feeding not tolerated)
Study: 11965831
Drug: Cholesterol lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol lowering therapy
Study: 11965831
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy with aspirin
Study: 11965831
Drug: Multifactorial approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial approach (including improved glycaemic control, aggressive management of dyslipidaemia and hypertension, anti-platelet therapy, reduction of insulin resistance)
Study: 1922250
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2 g per day of elemental calcium in the form of calcium carbonate)
Study: 28327089
Drug: De-escalation of
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation of elective radiation dose with introduction of an intermediate dose-level for selected lymph nodes.
Study: 28327089
Drug: Standard elective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard elective radiation dose without de-escalation.
Study: 26489756
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help (GSH) based on cognitive behaviour therapy (CBT)
Study: 21234579
Drug: Choline citrate
Normalized name: Choline citrate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline citrate (300.2 mg intravenously every 12 hours until defecation)
Study: 17306222
Drug: Internet administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet administration of the Obsessive Compulsive Inventory and the Obsessive Beliefs Questionnaire-44
Study: 15469788
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg once a day
Study: 9586915
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy with warfarin (regimen I)
Study: 9586915
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy without warfarin (regimen II)
Study: 9586915
Drug: ACE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE chemotherapy
Study: 9586915
Drug: PCE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCE chemotherapy and RT
Study: 31420057
Drug: Oral Nigella
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nigella sativa oil (1000 mg per capsule, 2 capsules per day for 8 weeks)
Study: 28509813
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules per day for 8 weeks)
Study: 27347857
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) combined with eccentric training
Study: 22026565
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (average 6 hours over 6 months)
Study: 11903702
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy assessment and appropriate treatments/equipment before release
Study: 9346275
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg vaccine
Study: 9346275
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg vaccine
Study: 7946857
Drug: Fentanyl 2-ng
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2-ng ml-1
Study: 7946857
Drug: Fentanyl 1-ng
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1-ng ml-1
Study: 27547135
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mononuclear cell (BMC) injections
Study: 27547135
Drug: Cell‐free injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell‐free injections of a placebo
Study: 31806930
Drug: Ranibizumab injections
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab injections
Study: 24053892
Drug: Ranibizumab injections
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab injections + laser photocoagulation
Study: 21126238
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction with sevoflurane (S 1.5, 2.0, 2.5, 3.0)
Study: 21126238
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) with 2.5% thiopental 5 mg/kg
Study: 8060544
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg, four times daily)
Study: 3051873
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 1% mepivacaine with epinephrine
Study: 3051873
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 1% mepivacaine without epinephrine
Study: 3051873
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 1% mepivacaine with and without epinephrine
Study: 30156130
Drug: Herbal compress
Normalized name: Ulva compressa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal compress treatment
Study: 12870566
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg b.d.)
Study: 16204325
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg mane)
Study: 11112113
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 250 microg twice daily, FP 500 microg twice daily, FP 1,000 microg twice daily
Study: 11112113
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 400 microg twice daily, BUD 800 microg twice daily, BUD 1,600 microg twice daily
Study: 26108524
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E with 0.025% tretinoin cream
Study: 26108524
Drug: Urea-cream (placebo)
Normalized name: urea Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea-cream (placebo)
Study: 25014687
Drug: Lanreotide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (120 mg, once every 28 days for 96 weeks)
Study: 23060037
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 μg daily as selenized yeast)
Study: 18040528
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml elderberry extract (278 mg total anthocyanins)
Study: 18040528
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml elderberry extract (1852 mg total anthocyanins)
Study: 12380791
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg orally once daily for 3 weeks
Study: 12380791
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (cefazolin plus gentamicin/cephalexin) for 3 to 4 weeks
Study: 2290723
Drug: TAC (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (all formulations)
Study: 29752179
Drug: Lovaza (1.86
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza (1.86 g of EPA and 1.5 g of DHA daily)
Study: 15475488
Drug: Sildenafil, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil, 50 mg
Study: 9389781
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g (1 mg oestradiol) transdermal oestradiol gel continuously combined with 10 mg medroxyprogesterone acetate orally 12 days either monthly or every third month
Study: 2437753
Drug: Atracurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium infusion (0.5 mg X kg‐1 bolus followed by 0.29‐0.44 mg X kg‐1 X h‐1 maintenance infusion)
Study: 2437753
Drug: Atracurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium infusion
Study: 28893921
Drug: Dietary potassium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary potassium restriction with oral sodium polystyrene sulfonate if needed
Study: 25851691
Drug: Selexipag with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag with lopinavir/ritonavir (400/100 mg)
Study: 23504631
Drug: Anisodamine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisodamine treatment group
Study: 21392640
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (aspirin and clopidogrel and placebo)
Study: 19170145
Drug: Rhodiola rosea
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola rosea (SHR‐5) pills
Study: 19170145
Drug: ADAPT‐232 supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADAPT‐232 supplements
Study: 15288704
Drug: Regular daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular daily activities in control participants
Study: 15288704
Drug: Daily activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activities in depressed participants
Study: 11743593
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg five times daily (n=20)
Study: 11743593
Drug: Valacyclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1000 mg twice daily (equivalent to 694 mg acyclovir twice daily) (n=18)
Study: 8297222
Drug: Urapidil (30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (30mg twice daily, increased to 60mg three times a day)
Study: 3619586
Drug: Pizotifen (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen (1.5 mg/day)
Study: 31315908
Drug: Levosimendan 1
Normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 1 mg daily
Study: 31315908
Drug: Levosimendan 1
Normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 1 mg two times a day
Study: 27159420
Drug: Step down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step down dose of PPIs by half for 8 weeks
Study: 27159420
Drug: Continue with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue with the same dose of PPIs for 8 weeks
Study: 27159420
Drug: Step down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step down dose of PPIs by half
Study: 27159420
Drug: Continue with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue with the same dose of PPIs
Study: 26026502
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (6 g/day)
Study: 26026502
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (6 g/day)
Study: 15249757
Drug: Ibuprofen-lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen-lysine
Study: 2665062
Drug: N-acetylcysteine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (200 mg X 3)
Study: 31759295
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy for sexuality (MBCT-S) in PP group
Study: 31759295
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy for sexuality (MBCT-S) in PPHP group
Study: 22568247
Drug: Diacerein (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein (50 mg Bid, Po) and Celecoxib (0.2 Qd, Po) (control group)
Study: 19195842
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg bid
Study: 17469006
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine (5 mg as a slow bolus dose given intravenously, repeated every 20 minutes to a maximum of five doses)
Study: 17469006
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (20 mg in an intravenous bolus dose followed by 40 mg if not effective within 20 minutes, followed by 80 mg every 20 minutes to a maximum dose of 300 mg)
Study: 14751924
Drug: Intensive-timing induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive-timing induction therapy
Study: 11226111
Drug: Preincisional dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preincisional dextromethorphan (120 mg) IM 30 min before skin incision
Study: 9763820
Drug: Medication during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication during pregnancy
Study: 7529535
Drug: CY +
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CY + etoposide + G‐CSF
Study: 2913556
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein capsules
Study: 2913556
Drug: Placebo (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (human albumin powder) capsules
Study: 1164007
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with valley levels over 2 mug/ml
Study: 1164007
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with peak levels over 10 mug/ml
Study: 1164007
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with peaks over 10 mug/ml
Study: 1164007
Drug: Gentamicin initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin initial doses of 2.0, 1.5, and 1.3 or less mpk
Study: 1164007
Drug: Gentamicin loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin loading dose of 2 mpk
Study: 1164007
Drug: Gentamicin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin at 4.5 mpk daily
Study: 1164007
Drug: Gentamicin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin at 3.0 mpk daily
Study: 31032356
Drug: Caudal Block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal Block (CB) with a dose of 0.5 ml/kg
Study: 29257010
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (20 mg/kg before incision, 10 mg/kg at 3, 6, 12, and 24 hours) + Topical TXA (1 g) without tourniquet
Study: 29257010
Drug: Tourniquet +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tourniquet + Intravenous TXA + Topical TXA
Study: 22379923
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg/day)
Study: 22379923
Drug: Pantoprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (80 mg/day)
Study: 19938143
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tacrolimus, azathioprine, and steroids)
Study: 17255126
Drug: ACEI+ARB combination
Normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI+ARB combination
Study: 15030341
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment applied once daily
Study: 15030341
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment applied twice daily
Study: 15030341
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone acetate (HA) ointment applied twice daily
Study: 15030341
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment (both once and twice daily)
Study: 11505807
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg daily for one month
Study: 11505807
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antihistamine)